Life Sciences Archive » April, 2023

Life Sciences - April, 2023

355 articles

• GoodRx, Google, Meta Privacy Suits Get Consolidated In Calif.
• NY Firm To Arbitrate $124K Fee Spat With Malaysian Co.
• Woman Says Hip Implant Releases Toxic Metals In J&J Suit
• Philips Loses Trade Secret Trial While Getting DMCA Damages
• Juul 'Leadership Reset' Not Altria's Call, Bellwether Jury Told
• Masimo Jury Ends Week With Drama, No Verdict, 1 Less Juror
• SPAC Investor Sues In Del. Over Digital Platform Value Plunge
• Novartis Tells 2nd Circ. To Affirm Win In Kickback Suit
• Judge Gives Texas Blue Cross Win In $2M Unpaid Claim Suit
• Bradley Arant Hires IP Partners From Holland & Knight
• Nonprofit Attys, Dinsmore Seek Swift End To LabMD Suit
• Titan Of The Plaintiffs Bar: Keller Rohrback's Lynn Sarko
• Taxation With Representation: Latham, Shearman, Kirkland
• Short Message Data Challenges In E-Discovery
• Judge Recommends Win For 3M In N95 Price-Gouging Suit
• CEO Concedes Youth Vaping Hike After Altria Investment
• Reps. Tell Vidal She Is Overstepping With USPTO Power
• Dykema Brings On Ex-SDNY Prosecutor From Saul Ewing
• Dem Lawmakers Tell USPTO To Do More On Drug Patents
• Merck Says It Paid $573M To Settle Zetia Antitrust Case
• IP Forecast: Gov't To Face Off Against Gilead In Delaware
• EU Proposes New Rules Governing Essential Patent Rows
• McKinsey, Plaintiffs Spar Over Picking Opioid Bellwether Tribe
• Philips Fights Claims Based On 'Competition' With SoClean
• 6th Circ. Urged To Turn Down Call To Reconsider FCA Ruling
• Chancery Trims Suit Over $110M Bioness-Bioventus Deal
• 2 Firms Steer Quest's $450M Cancer Research Firm Buy
• What's Next After High Court Stay On Abortion Pill Ruling
• 5 Firms Guide Drug-Delivery Firm's $374M SPAC Merger
• Federal Legislators Reintroduce SAFE Cannabis Banking Bill
• Eli Lilly Unable To Sink $61M Award In Drug Rebate Case
• 11th Circ. Backs Teacher's Jury Win In Disability Bias Suit
• Judge Abused Discretion In Abortion Pill Order, 5th Circ. Told
• Monsanto Insider's Roundup Tune Got Rosier, Jury Hears
• Top Juul Investor Facilitated, Got $2.45B From Altria Deal
• Cannabis Co. Inks $3M Investor Deal To End SEC Probe Suit
• Holmes' Prison Date Delayed As 9th Circuit Considers Bail
• Del. Judge Nixes Moderna Bid To Toss COVID Vax Patent Suit
• Tracon's $200M Damages Claim Axed In Cancer Antibody Feud
• FTC's Khan Says Antitrust Laws Favor 'Building Over Buying'
• Mich. Judge OKs Hospital Class Deal Over Vax Mandates
• Boston Lab Company Sues Rival Over 'SmartLabs' TM
• Ambiguity In 'Buy America' Implementation May Slow Projects
• Orbital Snags $270M Series A Financing To Build Out RNA Biz
• PG&E, Elizabeth Holmes Prosecutor Joins Jones Day
• Thomas Report Is Final Straw — High Court Needs Ethics Code
• Chancery Preserves Walmart Opioid Suit, Citing Redactions
• Altria Knew Juul Targeted Youth Before Investing, Jury Told
• COVID-19 Test Maker Investors Seek Final OK For $8.1M Deal
• PTAB Guts Most Of Fla. Biotech Co.'s Heart Valve Patent
• Apple Expert Slices Into Masimo's $3.1B Damages Theory
• More AI, More Problems, Attorneys Tell Patent Office
• Talc Claimants Move To Toss J&J Unit's Ch. 11
• Senators Target PBMs In Deal On 4 Drug Pricing Bills
• Insys Founder Says US Attorney 'Misled' Prisons Bureau
• J&J Flags Selendy Gay Conflicts In Robot Surgery Tech Suit
• Medtronic Wants Rival's Surgical Market Antitrust Claims Axed
• Diaper Genie Makers Want False Ad Suit Tossed
• Horse Assoc. Loses Discovery Bid As Suit Races Toward Trial
• Ill. Dispensary Escapes Black Fired Worker's Race Bias Suit
• FTC Pauses Illumina-Grail Order Amid 5th Circ. Appeal
• 10 Considerations When Licensing AI For Drug Discovery
• CVS Reaches $3.8M Settlement In Suit Over Lidocaine Labels
• Teva Seeks Escape From Feds' MS Drug Kickback Suit
• 2 Firms Lead Assertio Buy Of Spectrum Pharma For $248M
• Joint Representation Ethics Lessons From Ga. Electors Case
• Purdue Pharma Gets OK To Sell Over-The-Counter Business
• Ex-Worker Denied Sanctions Against Biotech Co. In 401(k) Suit
• 9th Circ. Asked To Back Abstention Over Pot License Program
• Fed. Circ. Backs UK Pharma Firm's IP Win Against CBD Giant
• Opioid Judge Rips UnitedHealth's 'Insulting' Coercion Charge
• Altria Created 'Vaping Crisis,' Jurors Told At Trial Kickoff
• Apple Seeks $3B Trial Win, Calls Masimo Tech 'Bits And Bobs'
• Merck, Glenmark Cut Deal With Last Group Of Zetia Buyers
• Corp. Arbitration Without Attorneys Present Upheld On Appeal
• NJ Pot Co. Worker Says She Was Fired For Age, Gender
• Judge Consolidates CBP Supervisor's Vaccine Mandate Suits
• Boston Scientific Investors Seek Class Cert. In Stock Suit
• Texas Doctor Will Pay $8M To Settle False Claims Suit
• Feds Ask 10th Circ. To Rethink Tribal Reimbursement Case
• Fed. Circ. Won't Revive Microscope Co.'s Patent Challenge
• Aurinia Shareholder Urges Strategic Review, Company Sale
• 2 Firms Lead Artificial Heart Tech Maker's $480M SPAC Merger
• Lawyer Discernment Is Critical In The World Of AI
• Biotech Co., Insurer Drop $3.6M Frozen Meds Shipping Suit
• Hologic-Minerva Medical Device Fight Ends Without Fees
• Regeneron Bid For Prosecutor Docs Falls Short, Judge Says
• Lilly's Sale Of Diabetes Drug To Amphastar Could Exceed $1B
• Cannabis Considerations In Debt Collection, Credit Reporting
• Catching Up With Delaware's Chancery Court
• Exclusion Bars Subpoena Expenses Coverage, Judge Says
• Law360 Reveals Titans Of The Plaintiffs Bar
• Monsanto Can't Move Roundup Trials, Mo. High Court Hears
• Indian Pharma Co. Can't Revive Claim Over Xifaxan Royalties
• Celgene, BMS, Teva Can't Pause Cancer Drugs Antitrust Suit
• Seminal Kickback Rulings Mean 'You're Rarely In A Safe Zone'
• SEC Wants Pot Pill Co., Promoter's Fraud Suits Consolidated
• J&J Talc Claimants Form Committee To Support Ch. 11 Plan
• Supreme Court Preserves Abortion Pill Access, For Now
• Comparing 2 Approval Processes For Gene Therapies
• Philly-Area Medical Device Co. Pays $5.3M To End FCA Case
• House Bill Introduced To Allow Legal Pot Users To Buy Guns
• Medical Software Customers Want Data Breach Suits Joined
• Doc Who Risked $100M In Options Snared In COVID Fraud Net
• Fed. Circ. Won't Reconsider Reviving Bard Patents
• Senators Plot Sweeping Action On Pharmacy Intermediaries
• Merck, Glenmark Cut Deal With End Payors Before Zetia Trial
• Judge Rejects $15M Deal, Tells Atty 'I Don't Bargain With You'
• 9th Circ. Snuffs Out CBD Co.'s Appeal Of Tax Arbitration Order
• Don't Forget Alumni Engagement When Merging Law Firms
• Feds Say Justices Should Reject Appeal From Ex-Shkreli Atty
• Mallinckrodt Trust Can't Be Used To Pay Attys In Opioid MDL
• Attorney Conflict Dooms Arb. Win In Software Dispute
• Interstate Cannabis Commerce May Be In Reach, With Caveats
• DLA Piper Malpractice Suit Over Gummy Deal Dropped
• Monsanto Argues Citizenship Wasn't Needed For $413M Deal
• No J&J Talc Trials For 60 Days, Bankruptcy Judge Rules
• Senate Panel Advances 7 Judicial Picks, Delays Others
• UK Says $125M Hearing Implants Merger Could Hurt Patients
• NY Courts Say Vax Mandate Suit Is Been There, Done That
• Fed. Circ. Won't Let Sandoz Break Into Amgen's Otezla Market
• Altria Can't Bar School's 'Sparkly' Video From Vaping Trial
• Expert Challenges Aren't 'Helpful,' Flint Judge Tells VNA Attys
• Abortion Pill Maker Fights FDA To Protect Drug Approval
• Gilead, Janssen, Teva Can't Say HIV Drug Costs Passed On
• Calif. AG Defends New Weedkiller Cancer Warnings At 9th Circ.
• GNC Says 'Lean' Bars Are About Lifestyle, Not Fat Content
• HIV Drug Patients Fight Gilead's Bid To Toss Plaintiffs
• City of Dearborn Sues Trucking Company Over Dust Pollution
• Distributors Push 4th Circ. To Uphold Opioid Verdict
• Brooklyn Law Clinic Urges Justices To Review AI Inventorship
• 3M Respirator Suits Belong In Federal Court, 6th Circ. Says
• Inovio Investors Want 1st OK For COVID-19 Derivative Deal
• Feds Float Security Limits On Export Of Protein Synthesizers
• PTAB Upholds DNA Testing Patents Key To $272M Ravgen Win
• 5th Circ. Fast-Tracks Illumina's Grail Appeal
• Without Stronger Due Diligence, Attys Risk AML Regulation
• UMich Teacher's Discrimination Claims Sent To State Court
• Calif. Ruling May Sow Seeds Of Cannabis Patent Precedent
• Ore. Licenses First Psilocybin Therapy Facilitators
• Bracewell Adds Holland & Knight Health Pro In San Antonio
• Emory University's Ex-Legal Chief Joins Ropes & Gray In DC
• Alito Extends Freeze On Abortion Pill Rulings
• Bristol-Myers Unit Seeks To Revive Blood Thinner Patent
• 1st Circ. Says Jury Poll Gaffe In Civil Case Merits New Trial
• Landmark FCA Showdown Looking Like Defense Bar Letdown
• Elizabeth Holmes Fights 'Unjust' Conviction At 9th Circ.
• Abortion Pill Foes Tell Justices FDA 'Federalized Abortion'
• ​​​​​​​High Court Poised To Reject Objective FCA Scienter Rule
• Ga. Justices Consider Challenge To Opioid Litigation Law
• J&J Unit Knowingly Marketed Faulty Knee-Device, Suit Says
• Talc Claimants Attack Suit Injunction In J&J Unit's Ch. 11
• HHS Head Flouted Hatch Act, Investigation Finds
• Investors Settle Out Of SEC Insider Trading Suit, Fines TBD
• Aid To Illegal Drug Imports Kills Price Checker's Antitrust Suit
• W.Va. County Urges 4th Circ. To Revive Opioid Distributor Row
• Abortion Pill Rulings Will Hinder FDA Authority
• Red Cross Says Biotech's Antitrust Suit Makes No Sense
• 2 Firms Vie To Lead Investor Suit Over Co.'s COVID Claims
• Cannabis Labor Peace Laws Lay Fertile Ground For Unions
• 6th Circ. Mulls New CAFA Standard In 3M Respirator Suits
• Every Lawyer Can Act To Prevent Peer Suicide
• Covington To Open Boston Office With Life Sciences Focus
• Ex-NJ Firefighter Gets 3 Years For Role In $50M Drug Fraud
• Merck, Glenmark Settle With Direct Purchasers In Zetia Case
• 4 Firms Guide GSK's $2B Bellus Cough Drug Co. Takeover
• US Cos. Racked Up $96B In Price-Fixing Fines Since 2000
• Ex-FDA Officials, Legal Scholars Rip Abortion Pill Ruling
• Receiver Dropped From $7M Fertilizer Case Over Funding
• Illumina Latest To Settle Out Of DNA Testing Patent Dispute
• Purged Cutera Chair And CEO Sue 'Rogue' Board In Delaware
• What To Watch In Pay-For-Delay Trial Against Merck, Glenmark
• Justices Won't Review Sanofi's Antitrust Suit Over EpiPen
• House Bills Look To Guide Federal Cannabis Legalization
• Justices Won't Review Bar On New Calif. Prop 65 Suits
• Illumina Pushes FTC For Full Pause Of Grail Order
• Catching Up With Delaware's Chancery Court
• 4 Firms Will Seek Up To $21M For Bioverativ Suit Settlement
• Justices Won't Take Up Novartis-HEC Feud Over MS Drug
• Building On Successful Judicial Assignment Reform In Texas
• Ropes & Gray Adds Career Shearman Atty In NY
• Juul, Minn. AG Ink Deal After Close Of Trial
• LivaNova Sued For €21M Over Soured Heart Biz Acquisition
• Paul Weiss, Latham Drive Merck's $10.8B Calif. Biotech Buy
• FCA Bar Jittery As 'Game-Changing Case' Goes To Justices
• Ex-Insys Directors Agree To $175M Ch. 11 Settlement
• The Sidley Atty Battling FCA Scienter Standard At High Court
• Importer Seeks To Clear Incontinence Underpants Of Tariffs
• The History-Making Atty In A Historic FCA High Court Fight
• Deposition Do-Over Ordered In Diabetes Strip Fraud Suit
• SPACs Set Sights On Public Co. Targets Amid Market Distress
• How Lip Implant Ruling Has Affected Design Patent Disputes
• Medtronic Seeks New Patent Trial After $106.5M Verdict
• Shkreli Keeps Fighting 'Needlessly Crushing' Penalties
• 9th Circ. Upholds Health Care Co.'s Win In TCPA Suit
• Feds, Wash. Fight Red States' Bid To Join Abortion Pill Suit
• DOJ, Treasury Targeting Sinaloa Cartel's Fentanyl Supply Chain
• What To Watch In High Court's FCA Scienter Standard Case
• Ex-Rep. Seeks Lenient Sentence For COVID Relief Schemes
• Ga. Needs To Resolve Cannabis Counsel Confusion
• 4th Circ. Backs UVA In Student Suit Alleging Anti-Swiss Bias
• McGinnis Lochridge Adds Ex-Nexsen Pruet Agribusiness Atty
• Health Hires: Generation Bio, Sunrider, Eiger
• Justice Alito Keeps US Access To Abortion Pill, For Now
• What To Know About 5th Circ.'s Midnight Abortion Pill Ruling
• Investors Fight For Class Cert. In Bayer Securities Fraud Suit
• Apple Exec Denies Hiring Cercacor CTO To Steal Watch Tech
• Alexion Investors Win Class Cert. Over Drug Sale Tactics
• Fla. Lawmakers Pass Bill Banning Abortions After 6 Weeks
• FTC Staff Say Full Pause Of Illumina Order Too Risky
• Medical Device Co. Calls Kickback Claim Nearly 'Sanctionable'
• Justices Told 'Billions' At Stake In AI Patent Crusade
• NC Families Push Again To Join Dow Asbestos Cancer Suits
• Fieldfisher Taps CBD Expert As Partner In London
• Now Is The Time For Independent Industry Self-Regulation
• FTC Warns Companies Not To Make Unbacked Health Claims
• Stockholders Partially Settle Bioverativ Suit In Del. For $84M
• AmEx Ruling Proves A Double-Edged Sword In Labor Antitrust
• Hartford Settles Ex-Salesman's Suit Over Disability Benefits
• McCarter & English Hires Baker Botts IP Expert In DC
• Covington Partner Must Testify Live In Zetia Trial, Judge Told
• 6th Circ. Says Scientist Must Pay $1M For Worthless Research
• DOJ To Take 5th Circ. Abortion Pill Ruling To Supreme Court
• Monster's Injunction Drops Bomb On Bang's 'Super Creatine'
• Merck, Glenmark Can Introduce 'Justifications' In Zetia Trial
• 5th Circ. Partly Stays Texas Judge's Abortion Pill Ruling
• US Tells Justices Ex-Interim USPTO Chief Had Review Power
• BioPharma Co. Escapes Investor Tumor Therapy Suit
• Investors Allege Caribou Oversold Cancer Therapy's Promise
• Abortion Pill Battle Puts Squeeze On Drug Benefit Managers
• Full 6th Circ. Urged To Revisit Circuit-Splitting FCA Hiring Case
• Danco Laboratories To Settle Marking Duties Suit For $765K
• Fed. Circ. Won't Revive Parkinson's Drug Patent
• 11th Circ. Vacates $8M Brain Supplement Deal
• Most Walmart Opioid Suit Claims Are Timely, Chancery Says
• Corcept Inks $14M Investor Deal Over Off-Label Drug Sales
• Fed. Circ. Breathes New Life Into IP Suit Against Philip Morris
• LifePoint Health Hit With OT Suit Over Kronos Hack
• Novartis Files Suit To Stop Chinese Entresto Generic
• Endo Gets OK For $27M Deal With Novavax In Contract Fight
• HHS Pitches Rule To Beef Up Abortion Privacy Protections
• More Indictments Possible In Merck Insider Case, Judge Told
• Do Videoconferences Establish Jurisdiction With Defendants?
• Juul To Pay $462M To End Predatory Marketing Claims
• Insys Founder Is No Threat, But May Not Get Early Release
• Starbucks Names Ex-Pfizer, Medtronic Atty As GC
• Apple Exec Voiced Concern About Sensor Efforts, Jury Hears
• Standing May Prove To Be Abortion Pill Ruling's Achilles' Heel
• Purdue Loses Case To Stop Generic OxyContin
• 240 Lawmakers See 'Imminent Harm' From Mifepristone Order
• Latham, Akin Attys Sank DNA Patent Row, Suit Says
• J&J Unit Ch. 11 Judge Slows Pace On Renewed Dismissal Try
• Elizabeth Holmes Can't Stay Free During Appeal, Judge Rules
• GSK Slams SG's Call To Tackle Skinny Labels At High Court
• Pharma Cos. Launch 2nd Gout Antitrust Case Against Takeda
• Generative AI Brings A New Generation Of Legal Issues
• Mallinckrodt Wants Out Of Manhattan Project Waste Suit
• Moderna Gets Fed. Circ. To Affirm Ax Of MRNA Patent
• Mich. County, Atty Sanctioned For Opioid Deal Challenge
• Allergan To Get Bulk Of $39M Drug Patent Win Over Sandoz
• EPA Floats New Ethylene Oxide Controls For Sterilizers
• AG's Cannabis Remarks Incongruous With Scheduling Review
• Humanism Should Replace Formalism In The Courts
• Viatris Wants To Rein In Neurim's Melatonin Patent Damages
• Outcome Health Execs Convicted Of Fraud
• Blackstone Wraps Up Record $30B Real Estate Fund
• DOJ Asks 5th Circ. To End 'Misguided' Abortion Pill Order
• Tivity Seeks Quick Win In Investors' Nutrisystem Buy Suit
• Masimo Exec Testifies To Secrecy Steps In $3B Apple Trial
• Feds Say ERISA, Medicare Preempt Part Of Okla. PBM Law
• Talc Claimants Call J&J Unit's New Ch. 11 Fraudulent
• Feds Say Alaskan Homebuilder Polluted River Without Permit
• Judge Says J&J Removed Hip Implant Suit To Cause Delay
• Navajo Hospital Wants $21M For Alleged IHS Contract Breach
• Dems Question SVB Depositors On Bank's 'Backscratching'
• NYC Man Admits Insider Trading On Merck Merger Secrets
• Online Lens Reseller Tries To Slide Out Of TM Fight Again
• W.Va. Strikes $7.9M Juul Deal Over Youth Marketing
• Pharma Execs Slam Abortion Pill Ruling, Citing Industry Risk
• CVS Wants HIV Patients' Disability Bias Suit Tossed
• Catching Up With Delaware's Chancery Court
• Masimo Co-Founder Hazy On Co.'s Claims In $3.1B Apple Suit
• J&J's New Talc Ch. 11 A Rehash Of Nixed Case, Claimants Say
• Texas Judge Pushes Pause On FDA Abortion Drug Approval
• 'Critically Sensitive' Kickback Issue Hurtles Toward High Court
• Medical Software Venture Opens Del. Ch. 11 With $33M Debt
• High Court Told FCA Knowledge Standard Clearly Subjective
• 7th Circ. Sides With Northwestern In Ex-Lab Tech's FMLA Suit
• Expect Merger Enforcement To Roll Full Steam Ahead
• Balwani Can't Dodge Prison Pending Appeal, 9th Circ. Says
• Catalyst Investors Ask Chancery To Pause Asia Purchase Vote
• IPO Prospects Seek Calm After Turbulent Start To 2023
• Insys Ch. 11 Trustee Slams Kapoor's Legal Fee Clawback Bid
• Del. Judge Certifies Appeal In Amgen, Teva Sensipar Case
• J&J Unit's Rival Loses Bid To Arbitrate Trade Secret Claims
• Masimo Execs Testify Behind Closed Doors In $3B Apple Trial
• Feds Want Prison For Trader In BigLaw Info Theft Case
• Fed. Circ. Roundup: PTAB Upheld, NeoMagic's Fee Bid Denied
• EPA Floats Cutting Ethylene Oxide, Other Chemical Emissions
• IP Forecast: Del. Judge Set To Turn Up Heat In Funding Probes
• FDA Revokes Clearance For Premature Birth Drug Makena
• Purdue Seeking OK To Put Over-The-Counter Biz Up For Sale
• Key Guidelines For Conducting Clinical Trials Overseas
• USPTO Says Revival Of Fintiv Suit Doesn't Help AstraZeneca
• Davis Graham Loses Patent Attorney To Kutak Rock
• Bristol-Myers, Dana-Farber Settle Cancer IP Dispute
• Doctor Tells 11th Circ. EPA Doesn't Bar Roundup Warning Suit
• Don't Let Client Demands Erode Law Firm Autonomy
• Distressed Cannabis Cos. Have A Few Options, With Caveats
• J&J Talc Plaintiffs Say Future Claims Rep Went Too Far
• COVID Fund Scammer To Appeal 8-Year Sentence
• Verily Life Sciences GC Joins Legal Defense Fund Board
• Outcome Health's Execs Knew Its Fraud The Best, Jury Hears
• Masimo Wants $3B From Apple Over Smartwatch IP, Jury Told
• Canine Implant Patent Fight Settles After J&J's $60M Trial Win
• Illumina To Appeal FTC's Grail Unwinding To 5th Circ.
• 4th Circ. Punts Pelvic Mesh Case Question To W.Va. Justices
• Health Groups Tell 5th Circ. FDA Right To Deny Vape Products
• Icahn Calls For Illumina CEO's Ouster Amid Its Battle With FTC
• Christian Clinic Seeks Review Of Axed Religious Bias Suit
• Texas Lab Inks $5.9M To Settle Kickback Allegations
• 6th Circ. Ruling's Seismic Shift In FCA Kickback Causation
• Why Event-Driven Securities Class Actions Often Succeed
• Arranta Prevails In Del. Noncompete Suit Filed By PSG
• Ex-Novartis VP, Former Prosecutor Joins Mandelbaum Barrett
• Medical Device Execs Buried Lead Test Defects, Feds Say
• Pfizer, Others Escape Patient Assistance RICO Suit, For Now
• Keep Your Apple Watches At Home, Judge Tells Masimo IP Jury
• Ex-Amarin CEO Says Hostile Takeover Cost Him His Job
• Skadden Adds Former Co-Head Of Proskauer's Trial Practice
• THC False Ad Plaintiffs Want Atty Fee Bid Tossed
• Jazz Overcharged For Narcolepsy Drug, Suit Alleges
• Dem AGs Support Rolling Back ACA Birth Control Exemption
• 5th Circ. Revives Biotech Co. Trade Secrets Suit Against Exec
• Lucira Stock Sale Not Blocked By Ch. 11 Stay, Judge Says
• Pfizer Draws Patent Suit Over COVID Vaccine
• 2 EU Laws Could Supercharge Product Liability Class Actions
• Gilead, DOJ Allowed To Redact Remaining Docs In Patent Row
• J&J Talc Unit Refiles For Ch. 11 With $8.9B Deal
• House Introduces Bill To Let Vets Access Medical Pot
• The Implications Of Moderna's Vaccine IP Defense Strategy
• Provention Investor Sues To Stop $2.9B Sanofi Merger
• 9th Circ. Says Insurer Can Recoup $2M Stem Cell Injury Outlay
• Cardinal Health Cuts $109M Deal In Suit Over J&J Unit Buy
• Ignore Big Pharma's Faux 'Facts,' HHS Says In Kickback Clash
• Nursing Home Co. Can't Shed 'Worthless Services' FCA Suit
• Chancery Rules Merck Kept Talc Liabilities In $14B Merger
• Judge Won't Triple PureWick's $28M Catheter Patent Win
• Texas Gets Win Over Head Start Vax Mandates
• Medtronic Wants 'Untenable' Insulin Pump Stock Suit Tossed
• Sentence For Conn. COVID Fraud Soars Above Guidelines
• Humana Sues Pharma Cos. Over Antipsychotic Generic Deal
• Catching Up With Delaware's Chancery Court
• Federal Judge's Amici Invitation Is A Good Idea, With Caveats
• FTC Orders Illumina To Unwind Grail Deal